SignaCor Therapeutics

SignaCor Therapeutics is a clinical-stage biotech company developing Cardiaza, a patented epigenetic modifying therapy for symptomatic hypertrophic cardiomyopathy (HCM). This pioneering treatment goes beyond mere symptom management, targeting the underlying disease pathology by harnessing DNA methylation. Cardiaza addresses multiple disease mechanisms, including established fibrosis, cardiomyocyte hypertrophy, and inflammation, aiming to improve cardiac structure and function, positioning it as a first-in-class approach.

The company was founded and spun out of Queen’s University Belfast in 2024, led by Dr. Chris Watson. Its foundation rests on over a decade of research and development conducted collaboratively between University College Dublin and Queen’s University Belfast. This extensive research identified key global DNA methylation changes in various cardiac pathologies, revealing that DNA methylation inhibition significantly reduces pathological fibrosis and improves cardiac function, forming the core insight for Cardiaza.

SignaCor focuses on patients suffering from symptomatic hypertrophic cardiomyopathy, with its therapy aimed at improving their prognosis and overall outcomes. The company's mission is to develop first-in-class cardiac therapies that redefine the standard of care for symptomatic HCM and other cardiac disorders, delivering significant patient impact globally.